SEPROGADIC – serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy

[1]  Ming Tang,et al.  Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression. , 2018, Cancer letters.

[2]  W. Murphy,et al.  Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control. , 2017, International journal of radiation oncology, biology, physics.

[3]  Matthias Mann,et al.  Revisiting biomarker discovery by plasma proteomics , 2017, Molecular systems biology.

[4]  H. McArthur,et al.  Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. , 2017, International journal of radiation oncology, biology, physics.

[5]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[6]  Ralph R. Weichselbaum,et al.  Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy , 2016, Nature Communications.

[7]  Chris Sander,et al.  Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome , 2016, Cell.

[8]  Y. Zhuang,et al.  Altered phenotypic and functional characteristics of CD3+CD56+ NKT-like cells in human gastric cancer , 2016, Oncotarget.

[9]  M. Osti,et al.  Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients? , 2016, World journal of gastroenterology.

[10]  D. Hwang,et al.  Integrated analysis of global proteome, phosphoproteome, and glycoproteome enables complementary interpretation of disease-related protein networks , 2015, Scientific Reports.

[11]  Akhilesh Pandey,et al.  Identification of differentially expressed serum proteins in gastric adenocarcinoma. , 2015, Journal of proteomics.

[12]  R. Aebersold,et al.  Non-invasive prognostic protein biomarker signatures associated with colorectal cancer , 2015, EMBO molecular medicine.

[13]  J. T. Jørgensen.  Clinical application of companion diagnostics. , 2015, Trends in molecular medicine.

[14]  Jason G. Jin,et al.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes , 2015, Nature Medicine.

[15]  Cheolju Lee,et al.  Impact of data-dependent exclusion list based mass spectrometry on label-free proteomic quantification. , 2015, Rapid communications in mass spectrometry : RCM.

[16]  David L. Tabb,et al.  Wavelet-Based Peak Detection and a New Charge Inference Procedure for MS/MS Implemented in ProteoWizard’s msConvert , 2014, Journal of proteome research.

[17]  Chao He,et al.  Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients. , 2014, International journal of clinical and experimental pathology.

[18]  Youngsoo Kim,et al.  Detection and quantification of plasma amyloid-β by selected reaction monitoring mass spectrometry. , 2014, Analytica chimica acta.

[19]  Erik Sjölund,et al.  Fast and accurate database searches with MS-GF+Percolator. , 2014, Journal of proteome research.

[20]  Aditi Chatterjee,et al.  Plasma Proteome Database as a resource for proteomics research: 2014 update , 2013, Nucleic Acids Res..

[21]  John D Lambris,et al.  The role of complement in tumor growth. , 2014, Advances in experimental medicine and biology.

[22]  W. Kisiel,et al.  Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer , 2013, Annals of Hematology.

[23]  Nandini A. Sahasrabuddhe,et al.  SILAC‐based quantitative proteomic analysis of gastric cancer secretome , 2013, Proteomics. Clinical applications.

[24]  Tae Hyun Kim,et al.  Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. , 2012, International journal of radiation oncology, biology, physics.

[25]  Luis Mendoza,et al.  PASSEL: The PeptideAtlas SRMexperiment library , 2012, Proteomics.

[26]  A. Baghestani,et al.  How to control confounding effects by statistical analysis , 2012, Gastroenterology and hepatology from bed to bench.

[27]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Ruedi Aebersold,et al.  On the development of plasma protein biomarkers. , 2011, Journal of proteome research.

[29]  S. Natsugoe,et al.  Clinical implication of CD166 expression in gastric cancer , 2011, Journal of surgical oncology.

[30]  M. Loh,et al.  Upregulation of plasma C9 protein in gastric cancer patients , 2010, Proteomics.

[31]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[32]  Nichole L. King,et al.  The PeptideAtlas Project , 2010, Proteome Bioinformatics.

[33]  M. Imamura,et al.  Clinicopathological significance of aminopeptidase N/CD13 expression in human gastric carcinoma. , 2007, Hepato-gastroenterology.

[34]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[35]  Bert Vogelstein,et al.  The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.

[36]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[37]  Eric W. Deutsch,et al.  The PeptideAtlas project , 2005, Nucleic Acids Res..

[38]  Ron Edgar,et al.  Gene Expression Omnibus ( GEO ) : Microarray data storage , submission , retrieval , and analysis , 2008 .

[39]  Graham B. I. Scott,et al.  HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples , 2005, Proteomics.

[40]  Akhilesh Pandey,et al.  Plasma Proteome Database as a resource for proteomics research , 2005, Proteomics.

[41]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[42]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[43]  A. Nashimoto,et al.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Gouma,et al.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  F. Vizoso,et al.  Prognostic value of cytosolyc cathepsin D content in resectable gastric cancer , 2004, Journal of surgical oncology.

[46]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[47]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[48]  N. Anderson,et al.  HISTORY, CHARACTER, AND DIAGNOSTIC PROSPECTS* , 2002 .

[49]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[50]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[51]  M. Štabuc-Šilih,et al.  Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. , 2000, Clinical chemistry.

[52]  Y. Doki,et al.  Characterization of soluble E-cadherin as a disease marker in gastric cancer patients. , 1998, British Journal of Cancer.

[53]  R. Lozano,et al.  [Immunologic responses following surgical resection of gastrointestinal carcinomas]. , 1984, Revista espanola de oncologia.